Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants. Issue 8 (18th February 2020)

• Record Type: Journal Article
• Authors: Fadlyana, Eddy; Dhamayanti, Meita; Tarigan, Rodman; Mulia Sari, Rini; Sjafri Bachtiar, Novilia; Kartasasmita, Cissy B.; Rusmil, Kusnandi
• Is Part Of: Vaccine. Volume 38:Issue 8(2020)
• Page Start: 1962
• Page End: 1967
• Publication Date: 2020-02-18
• Subjects: GMT geometric mean titre -- GPEI global polio eradication initiative -- IPV inactivated poliovirus vaccine -- OPV oral polio vaccine -- VAPP vaccine-associated paralytic poliomyelitis -- cVDPV circulating vaccine-derived poliovirus -- WHO World Health Organization; bOPV -- IPV -- Immunogenicity -- Pentabio -- Safety; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.01.007
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Four bOPV doses and 1 IPV dose resulted in high seroprotection for P1, P2, and P3. Despite only had 1 dose of P2 in IPV, subjects have high seroprotection for P2. There was no systemic event during 30 min after birth dose of bOPV. Abstract: In this study, we aimed to evaluate the immunological protectivity of infants following four doses of bivalent oral polio vaccine (bOPV; Bio Farma), which were given simultaneously with DTwP-Hb-Hib (Pentabio®), along with one dose of inactivated poliovirus vaccine (IPV) at the fourth visit. A total of 143 newborn infants who fulfilled the inclusion criteria were enrolled and completed the study. Subjects received the first dose of bOPV at birth. On days 60, 90 and 120, bOPV was given simultaneously with Pentabio®. On day 120, one dose of IPV was also administered. Serum samples for serology analysis were collected before the first dose of bOPV (at day 0), before the second dose of bOPV (at day 60) and 30 days after the last dose of bOPV. In addition, the intensity, duration and relationship of each adverse event to the trial vaccines were assessed. Seroprotection rates after the fourth dose of bOPV were 100%, 91.6% and 99.3% for poliovirus P1, P2 and P3, respectively. Seroconversion rates after the fourth dose of bOPV were 100.0%, 93.3% and 100% for poliovirus P1, P2 and P3, respectively. There were no severe adverse events, and systemic reactions were generally mild during the 1–28 day post-vaccination period. Collectively, our findings indicate that bOPV given simultaneously with Pentabio® and one dose of IPV at the 4th visit was immunogenic and well tolerated.